Tag Archives: Oren Livnat

H.C. Wainwright Reiterates Their Buy Rating on Pacira Pharmaceuticals

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $48. The company’s shares opened today at $35.60. Livnat said: “Valuation and risks. Our $48 12-month

BioDelivery Receives a Buy from H.C. Wainwright

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $3.50. The company’s shares opened today at $2.90. Livnat wrote: “Valuation and risks. We assume Belbuca continues

Analysts Are Bullish on These Healthcare Stocks: ZYNE, BSX

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Boston Scientific Corp (NYSE: BSX) with bullish sentiments. Zynerba Pharmaceuticals (ZYNE) In a report released today, Oren

H.C. Wainwright Thinks Cara Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Cara Therapeutics (NASDAQ: CARA) today and set a price target of $24. The company’s shares opened today at $13.60, close to its 52-week low of $11.11. Livnat commented: “We view

H.C. Wainwright Thinks MannKind’s Stock is Going to Recover

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on MannKind (NASDAQ: MNKD), with a price target of $5. The company’s shares closed yesterday at $1.79, close to its 52-week low of $1.01. Livnat wrote:

Agile Therapeutics Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $8. The company’s shares closed yesterday at $2.83. Livnat said: “FDA Exchange NASDAQ Value (M) $76.9 Market Cap (M)